Teva Pharmaceutical Industries Ltd (TEVA)

32.95
0.34 1.04
NYSE : Health Care
Prev Close 32.61
Open 32.85
Day Low/High 32.77 / 33.41
52 Wk Low/High 27.59 / 56.44
Volume 6.90M
Avg Volume 7.64M
Exchange NYSE
Shares Outstanding 1.02B
Market Cap 33.04B
EPS 0.10
P/E Ratio 6.33
Div & Yield 1.36 (4.20%)

Latest News

Chart of the Day: Teva

The money flow has turned positive.

FDA Commisoner Takes on Big Pharma

FDA Commisoner Takes on Big Pharma

Investors should watch these companies come July 18th.

Teva Pharmaceuticals Upgraded at Mizuho

Teva Pharmaceuticals Upgraded at Mizuho

Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.

Opioid Marketing Under Bipartisan Investigation

Opioid Marketing Under Bipartisan Investigation

Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..

Teva Announces Launch Of Generic Zetia® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Zetia ®1 (ezetimibe) tablets, 10 mg, in the U.

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Pharmaceutical Stocks Gain on Promising Migraine Drugs with Hefty Price Tags

Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.

Teva Pharmaceutical Stock Rising on Generic Eye Drop Launch

Teva Pharmaceutical Stock Rising on Generic Eye Drop Launch

The drops are used to treat itchy eyes associated with allergies.

Teva Announces Exclusive Launch Of Generic Pataday® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Pataday ®1 (olopatadine hydrochloride ophthalmic solution) 0.

Teva's Fremanezumab Meets All Primary & Secondary Endpoints Across Both Monthly And Quarterly Dosing Regimens In Phase III Study In Episodic Migraine Prevention

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced positive results from the second Phase III HALO study of fremanezumab (TEV-48125), an investigational treatment for the prevention of migraine.

Teva To Present At The Jefferies 2017 Global Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Jefferies 2017 Global Healthcare Conference in New York, NY.

Teva To Present Data From 18 Abstracts In Tardive Dyskinesia And Huntington Disease At The 21st International Congress Of Parkinson's Disease And Movement Disorders

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced data for deutetrabenazine tablets for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease (HD), and pridopidine...

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's Quarterly Loss was a Staggering $708 Million, Key Exec Leaves

Uber's first quarter loss was less than the $991 million loss reported 3 months ago.

Teva Announces Positive Results For Phase III Study Of Fremanezumab For The Prevention Of Chronic Migraine

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced positive results from a Phase III HALO study of fremanezumab, an investigational treatment for the prevention of migraine.

Foot Locker, Cara Therapeutics, National Grid, TripAdvisor: 'Mad Money' Lightning Round

Foot Locker, Cara Therapeutics, National Grid, TripAdvisor: 'Mad Money' Lightning Round

Jim Cramer is bullish on Foot Locker, Cara Therapeutics, National Grid, and Home Depot.

Step Away From the Ledge: Cramer's 'Mad Money' Recap (Wednesday 5/24/17)

Step Away From the Ledge: Cramer's 'Mad Money' Recap (Wednesday 5/24/17)

Jim Cramer says that when it comes to alarming negativity and ridiculous exuberance, both extremes are wrong; investors need to get real.

Teva Pharmaceutical Leaning Towards Foreigner as New CEO

Teva Pharmaceutical Leaning Towards Foreigner as New CEO

Israel's largest firm is also searching for a chief financial officer in which three candidates are vying for the position.

Teva Showcases Asthma Research At The 2017 American Thoracic Society (ATS) International Conference

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that eight company-sponsored abstracts will be presented at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.

Teva To Present Data For Deutetrabenazine In Tardive Dyskinesia At The American Psychiatric Association 2017 Annual Meeting

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced eight abstracts evaluating deutetrabenazine tablets - formerly referred to as SD-809 - for the treatment of tardive dyskinesia (TD) will be...

Teva Announces Launch Of Generic Glumetza® In The United States

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of generic Glumetza ®1 (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg, in the U.

Otsuka And Teva Sign Licensing Agreement For Japan On Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)

Otsuka Pharmaceutical Co., Ltd (Otsuka) and Teva Pharmaceutical Industries, Ltd.

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.

Teva Reports First Quarter 2017 Financial Results

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2017.

Teva And Active Biotech Announce CONCERTO Trial Of Laquinimod In RRMS Did Not Meet Primary Endpoint

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS).

Teva Announces Publication Of COPAXONE® (glatiramer Acetate Injection) Pregnancy Data In The International Journal Of MS Care

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that data suggests that women with relapsing forms of multiple sclerosis (RMS) who were exposed to COPAXONE ® 20 mg/mL daily during pregnancy...

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Teva Pharmaceutical Is Ready for a Tradable Rally

Teva Pharmaceutical Is Ready for a Tradable Rally

Prices are extended on the downside.